近日，美国心脏协会（AHA）、美国心脏病学会（ACC）等多家机构联合发布了新版成人高血压的预 防、检测、评估和管理指南，对2017年版指南进行了重要修订。新版指南在高血压的诊断、风险评估及 治疗等方面均有更新，旨在更精准地指导临床实践，降低心血管疾病（CVD）风险。其中，去肾神经 术（RDN）成为新增推荐的治疗方式。 另值得关注的是，此前有报道指，美国医疗保险和医疗补助服务中心（CMS）发布新RDN医保提案。 新提案建议将RDN纳入未控制高血压患者的医保覆盖范围。该提案已启动30天公众评议期，最终决定 预计于2025年10月8日或之前公布。 来源：新浪港股 百心安-B（02185）盘中一度涨超15%，高见10.77港元，创近二年多来新高，昨日收涨逾50%。截至发 稿，股价上涨7.63%，现报10.01港元，成交额6117.088万港元。 ...

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a rise of over 50% recently, driven by updates in hypertension management guidelines and potential insurance coverage for renal denervation (RDN) procedures [1]. Group 1: Stock Performance - Baixinan-B's stock rose over 15% at one point and closed up more than 50% yesterday, currently trading at 10.36 HKD with a trading volume of 42.644 million HKD [1]. Group 2: Industry Guidelines - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. Group 3: Insurance Coverage Proposal - The Centers for Medicare & Medicaid Services (CMS) proposed new insurance coverage for RDN, suggesting it be included for patients with uncontrolled hypertension [1]. - The proposal has entered a 30-day public comment period, with a final decision expected to be announced by October 8, 2025 [1].